BIO-CHEM(SH:603360)2025-04-24 13:00Financial Performance - The company's revenue for Q1 2025 was CNY 448.32 million, representing a year-on-year increase of 32.54% compared to CNY 338.25 million in the same period last year[4]. - Net profit attributable to shareholders decreased by 48.98% to CNY 50.16 million from CNY 98.31 million year-on-year[4]. - The basic earnings per share fell by 47.37% to CNY 0.10, down from CNY 0.19 in the previous year[4]. - Total operating revenue for Q1 2025 reached ¥448.32 million, a 32.6% increase from ¥338.25 million in Q1 2024[16]. - Net profit for Q1 2025 was ¥59.99 million, a decrease of 39.0% compared to ¥98.31 million in Q1 2024[17]. - The company reported a total comprehensive income of ¥60.17 million for Q1 2025, down from ¥96.12 million in Q1 2024[17]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.10, compared to ¥0.19 in Q1 2024[17]. Assets and Liabilities - The total assets at the end of the reporting period increased by 7.40% to CNY 3.91 billion from CNY 3.64 billion at the end of the previous year[5]. - As of March 31, 2025, the total current assets amounted to RMB 2,651,596,604.90, an increase from RMB 2,513,034,095.85 as of December 31, 2024, reflecting a growth of approximately 5.5%[12]. - The company's total equity increased to RMB 2,417,535,762.23 from RMB 2,351,197,323.20, reflecting a growth of approximately 2.8%[13]. - Total liabilities as of March 31, 2025, were RMB 1,491,485,198.98, compared to RMB 1,288,572,546.59 at the end of 2024, marking an increase of around 15.7%[13]. - Short-term borrowings rose to RMB 524,194,769.38 from RMB 423,937,895.84, indicating an increase of about 23.6%[13]. - The accounts receivable decreased to RMB 304,607,607.48 from RMB 342,044,792.01, showing a decline of approximately 10.9%[12]. - The company reported a decrease in contract liabilities from RMB 347,910,486.36 to RMB 226,842,838.22, a reduction of about 34.7%[13]. Cash Flow and Expenses - The net cash flow from operating activities was negative at CNY -59.64 million, worsening by 11.04% compared to CNY -53.72 million in the previous year[4]. - Cash flow from operating activities for Q1 2025 was negative at -¥59.64 million, compared to -¥53.72 million in Q1 2024[21]. - The company incurred a financial expense of ¥2.01 million in Q1 2025, compared to a financial income of -¥2.86 million in Q1 2024[16]. - Research and development expenses increased to ¥18.70 million in Q1 2025, up 80.6% from ¥10.34 million in Q1 2024[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,656[8]. - Major shareholder Dalian Tongyun Investment Co., Ltd. holds 29.96% of shares, with 20 million shares pledged[9]. Other Financial Metrics - The weighted average return on equity decreased by 3.06 percentage points to 2.77% from 5.83% year-on-year[4]. - The semiconductor business achieved a revenue of CNY 260 million, a year-on-year increase of 389.39% and a quarter-on-quarter increase of 35.19%[7]. - The company's cash and cash equivalents reached RMB 845,334,296.97, up from RMB 668,244,186.44, indicating a significant increase of about 26.5%[11]. - Inventory levels increased to RMB 937,607,900.95 from RMB 902,353,613.16, representing a rise of approximately 3.9%[12]. - The long-term investments in equity stood at RMB 122,827,058.57, with no previous figure provided for comparison[12]. - The company maintained a stable goodwill value of RMB 230,532,246.93, unchanged from the previous reporting period[12]. - The company experienced a foreign exchange gain of ¥1.68 million in Q1 2025, compared to a gain of ¥0.78 million in Q1 2024[22].